Background: Oral focal mucinosis (OFM) is a rare benign condition of unknown etiology, considered the oral counterpart of cutaneous focal mucinosis. We report the clinicopathologic features of 21 cases of OFM in conjunction with a review of the literature. Methods: Clinical data were collected from the records of five oral and maxillofacial pathology services. All cases were evaluated by hematoxylin and eosin staining, histochemistry, and immunohistochemistry (vimentin, S-100, α-SMA, CD34, and mast cell). Results: The series comprised 14 females (66.7%) and seven males (33.3%), with a mean age of 48.2 ± 20.7 years (range: 8-77 years) and a 2:1 female-to-male ratio. Most of the lesions affected the gingiva (n = 6, 28.6%) and presented clinically as asymptomatic sessile or pedunculated nodules with fibrous or hyperplasic appearance. All cases were negative for S-100 protein, CD34, and α-SMA and positive for Alcian blue staining. Conservative surgical excision was the treatment in all cases, and there was only one recurrence. Conclusion: OFM is a rare benign disorder that is often clinically misdiagnosed as reactive lesions or benign proliferative processes. Dermatologists and pathologists should consider OFM in the differential diagnosis of soft tissue lesions in the oral cavity, mainly located in the gingiva. K E Y W O R D S connective tissue diseases, diagnosis, oral focal mucinosis, oral pathology 1 | INTRODUCTION Oral focal mucinosis (OFM) is considered to be the oral counterpart of cutaneous focal mucinosis (CFM) that likely develops due to an overproduction of hyaluronic acid by fibroblasts. 1-3 As a result, a well-demarcated myxomatous tissue positive for Alcian blue (pH 2.5) is observed microscopically; which may mimic other oral myxoid lesions, such as soft-tissue myxoma, fibrous hyperplasia with myxoid degeneration, nerve sheath myxoma (NSM), myxoid neurofibroma, and mucocele. 1

Prospective evaluation of the buccal mucosa of pediatric patients with acute lymphocytic leukemia (ALL) regarding its clinical aspect and expression of members from the HHV family. Methods: From September 2014 to January 2015, a series of nine consecutive patients was evaluated, with ages ranging from 2 to 14 years, in treatment at the Amazon Hematology and Hemotherapy Foundation (HEMOAM). The buccal mucosa of those patients was clinically evaluated, screened for alterations and analyzed by PCR, to search DNA from HSV-1, CMV and EBV during four moments of the pre-phase/induction phase of the chemotherapy treatment (P/I)-D0/D1, D8, D15 and D35, as well as four moments of the consolidation of the remission phase (CR)-D1, D15, D29 and D50. The protocol proposed by the Brazilian Cooperative Group for Treatment of Childhood Lymphocytic Leukemia (GBTLI ALL-2009) was followed. Results: A prevalence of 2-year-old children (66.7%, n=6) with a diagnose of B-cell ALL (88.9%, n=8) was observed. Buccal alterations were observed in 33.3% (n=3) of the patients: erythema (D35 P/I), dry lips (D8 and D15 P/I) and an episode of xerostomia (D15 P/I). None of the samples was positive for HSV-1 and CMV, but 33.3% (n=3) of the cases expressed EBV (D8 and D15 P/I). Conclusions: Buccal alterations and the presence of HSV-1, CMV and EBV in patients with ALL was inexpressive, with most of the patients being sound throughout the treatment. Thus, it cannot be affirmed that the analyzed viruses are part of the microbiome of those patients. However, it has been suggested that the presence of EBV is more expected than

Objetivos: Avaliar clinicamente a mucosa bucal de pacientes infantojuvenis com leucemia linfoblástica. Métodos: Num período de doze meses, 36 pacientes com leucemia linfoblástica de células B ou T, entre 1 e 14 anos, tratados pelos protocolos GBTLI-LLA 2009 ou ALL IC-BFM 2009 foram consecutivamente localizados. A mucosa bucal foi clinicamente avaliada no início da pré- -fase/indução da quimioterapia e ao décimo quinto dia de tratamento. Resultados: Dos 25 pacientes que tiveram a mucosa bucal avaliada, 64% (n=16) eram do sexo masculino com média de idade de 6,9 anos e a maioria com leucemia linfoblástica de células B (96%; n=24). Desses, 44% (n=11) apresentaram manifestações bucais, sendo a maioria no início da pré-fase/indução da quimioterapia. As manifestações encontradas foram petéquias na mucosa bucal (31,6%; n=6), ressecamento labial (26,3%, n=5) e mucosite bucal (15,8%, n=3), sendo a mucosa não-queratinizada o sítio de predileção (84,2%, n=16). Conclusões: A frequência de manifestações bucais em pacientes infantojuvenis com leucemia linfoblástica é baixa, visto que a maioria dos pacientes neste estudo apresentou mucosa hígida. Esse facto pode estar relacionado com nossa baixa casuística ou ainda à baixa toxicidade dos protocolos adotados e equipa odontológica atuante na Instituição.

No abstract

No abstract

No abstract

No abstract

No abstract